BPC-157 and TB-500 peptide claims: what the science actually supports

What did @dr_cois actually say?

Dr. Cois, an emergency medicine physician, opened with a flat declaration: "No one should be taking peptides." He backed it up with a clinical anecdote about a patient who developed hives after injecting a peptide for hair and collagen benefits. His core argument is that these compounds "haven't been tested for human consumption" and lack FDA-approved safety and efficacy data. He closed by recommending exercise, protein intake, sleep, and a plant-based diet as alternatives.

To be fair to him, he is not wrong that the regulatory landscape for peptides sold outside of clinical trials is genuinely murky. But the sweeping claim that "no one should be taking peptides" collapses real distinctions between compounds with legitimate research behind them and ones with almost none. That kind of flattening does its own kind of harm to people trying to make informed decisions.

Does the science back this up?

Partly, but not entirely. The FDA has taken enforcement action against several peptides, including BPC-157 and TB-500, removing them from compounding pharmacy availability in the US. That regulatory reality is real. What is also real is that some peptides in this category have more human data than Dr. Cois implies.

GHK-Cu, for example, has been studied in human clinical trials for wound healing and skin repair going back decades. Pickart and Margolina (2018, Biomedicines) reviewed substantial human and animal data supporting its topical use. CJC-1295 and ipamorelin have been studied in human growth hormone secretion trials, including Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism), which showed measurable GH and IGF-1 responses in healthy adults. MK-677, technically not a peptide but a ghrelin mimetic, has human trial data including Nass et al. (2008, Annals of Internal Medicine). These are not robust phase 3 drug approval packages, but calling them completely uninvestigated overstates the case.

The hives anecdote is clinically plausible. Allergic and hypersensitivity reactions to injectable compounds, especially unregulated ones sourced outside pharmacy channels, are documented risks. That part holds up.

What did they get wrong (or right)?

He got the regulatory risk right. He got the accountability gap right. Peptides sold through unregulated online channels carry real contamination and dosing accuracy risks that are not theoretical. A 2023 study by Cohen et al. (JAMA Internal Medicine) on unregulated injectable compounds found significant labeling inaccuracies across product categories, which supports his concern.

What he got wrong is the absolutism. Saying these products "haven't been tested for human consumption" is inaccurate for several compounds in this category. It also ignores that some peptides, like Semax, are actually approved drugs in Russia and Eastern Europe with clinical use history. Selank similarly has regulatory status and published human trial data in those markets.

His comment about "a maniac at the head of our Health and Human Services" is an editorial choice that will alienate a significant portion of his potential audience. Whether you agree with that assessment or not, mixing political commentary into a safety message is a reliable way to make people tune out the parts that are actually useful.

His lifestyle recommendations are sound. The protein guidance of "one to 1.6 grams per kilo per day" aligns with the current evidence from Morton et al. (2018, British Journal of Sports Medicine) on resistance training and protein synthesis.

What should you actually know?

The honest answer is that peptide risk exists on a spectrum, and your actual exposure depends heavily on where the compound comes from, what it is, and how it is administered. Regulatory status in the US has tightened significantly. The FDA's removal of BPC-157 and TB-500 from 503A and 503B compounding lists means that sourcing these compounds now typically means going outside regulated pharmacy channels, which genuinely increases contamination and concentration risk.

The allergic reaction Dr. Cois described is a real possibility with any injectable compound, particularly one of unknown purity. That risk is not hypothetical. At the same time, framing all peptides as equally uninvestigated and equally dangerous is not an accurate picture of the research.

If you are considering any peptide therapy, the relevant questions are: Is it available through a licensed compounding pharmacy operating under current regulations? Has it been studied in humans at all? Do you have a clinician supervising the protocol who can monitor for adverse reactions? "Just avoid them altogether" is one defensible position. But for someone who has already decided to explore this category, that advice leaves them with nowhere to go except unregulated sources, which is the actual danger.